Luis Lara-Mejía, Medical Oncologist Specialized in Thoracic Neoplasms at National Institute of Cancerology, shared an article on X:
“New data from NJLCG 1902 (Phase 2):
Radiotherapy added to pembrolizumab and platinum-doublet chemo in 1L metastatic NSCLC:
- 12-mo PFS: 44.3%,
- median OS: 30.1 mo.
- Grade ≥3 AEs: 65.8%;
- Pneumonitis in 26.3% Protocol: RT (30 Gy/10 fx) started <7 days before systemic Tx.
Promising efficacy—but pneumonitis remains a concern.
Tagging para amplificar: IASLC, JTO & JTO CRR.”
Phase 2 Trial of Combination Radiotherapy and Pembrolizumab Plus Chemotherapy in Patients With Previously Untreated Metastatic NSCLC: NJLCG 1902.
Authors: Yoko Tsukita, Rei Umezawa, Taku Nakagawa, Akira Anbai, Tomonori Makiguchi, Hisashi Tanaka, Yosuke Horii, Aya Suzuki, Ryo Morita, Hitomi Nogawa, Hiroshi Yokouchi, Nozomu Kimura, Keiichi Jingu, Akira Inoue, Hisatoshi Sugiura, Eisaku Miyauchi.
You can read the Full Article on Journal of JTO Clinical and Research Reports.
More posts featuring Luis Lara-Mejía.
